State Of Wisconsin Investment Board Kodiak Sciences Inc. Transaction History

State Of Wisconsin Investment Board

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.3 - $9.48 $41,267 - $90,979	-9,597 Reduced 8.99%	97,200 $670,000
Q1 2023 May 15, 2023	SELL	$4.81 - $8.88 $80,937 - $149,423	-16,827 Reduced 13.61%	106,797 $662,000
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.05 $62,285 - $76,901	9,553 Added 8.37%	123,624 $885,000
Q3 2022 Nov 14, 2022	BUY	$7.57 - $12.5 $35,798 - $59,112	4,729 Added 4.32%	114,071 $883,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $9.48 $14,827 - $27,890	2,942 Added 2.77%	109,342 $835,000
Q1 2022 May 13, 2022	BUY	$7.09 - $89.45 $308,542 - $3.89 Million	43,518 Added 69.21%	106,400 $821,000
Q4 2021 Feb 11, 2022	BUY	$80.85 - $128.49 $410,152 - $651,829	5,073 Added 8.78%	62,882 $5.33 Million
Q2 2021 Aug 12, 2021	SELL	$77.2 - $126.54 $216,160 - $354,312	-2,800 Reduced 4.62%	57,809 $5.38 Million
Q1 2021 May 17, 2021	BUY	$110.45 - $164.47 $786,514 - $1.17 Million	7,121 Added 13.31%	60,609 $6.87 Million
Q4 2020 Feb 03, 2021	BUY	$60.78 - $154.03 $60,050 - $152,181	988 Added 1.88%	53,488 $7.86 Million
Q3 2020 Nov 16, 2020	BUY	$45.05 - $59.27 $337,875 - $444,525	7,500 Added 16.67%	52,500 $3.11 Million
Q2 2020 Aug 12, 2020	BUY	$42.74 - $66.25 $72,658 - $112,625	1,700 Added 3.93%	45,000 $2.44 Million
Q1 2020 May 06, 2020	BUY	$38.18 - $73.95 $301,622 - $584,205	7,900 Added 22.32%	43,300 $2.07 Million
Q3 2019 Nov 12, 2019	BUY	$10.24 - $17.57 $221,184 - $379,512	21,600 Added 156.52%	35,400 $509,000
Q2 2019 Aug 14, 2019	BUY	$6.2 - $12.0 $85,560 - $165,600	13,800 New	13,800 $161,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $288M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.